These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 1517556)

  • 41. Treatment of depersonalization with serotonin reuptake blockers.
    Hollander E; Liebowitz MR; DeCaria C; Fairbanks J; Fallon B; Klein DF
    J Clin Psychopharmacol; 1990 Jun; 10(3):200-3. PubMed ID: 2115893
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The serotonin hypothesis of obsessive compulsive disorder.
    Barr LC; Goodman WK; Price LH
    Int Clin Psychopharmacol; 1993 Nov; 8 Suppl 2():79-82. PubMed ID: 8201248
    [TBL] [Abstract][Full Text] [Related]  

  • 43. When fluvoxamine treats only depression and clomipramine treats only obsessive-compulsive disorder--combine them?
    Schaller JL; Behar D; Chamberlain T
    J Neuropsychiatry Clin Neurosci; 1998; 10(1):111-3. PubMed ID: 9547477
    [No Abstract]   [Full Text] [Related]  

  • 44. An integrated approach to treatment of obsessive compulsive disorder.
    Greist JH
    J Clin Psychiatry; 1992 Apr; 53 Suppl():38-41. PubMed ID: 1532963
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A pilot study of biological predictors of treatment outcome in obsessive-compulsive disorder.
    Hollander E; Stein DJ; DeCaria CM; Saoud JB; Klein DF; Liebowitz MR
    Biol Psychiatry; 1993 May; 33(10):747-9. PubMed ID: 8353170
    [No Abstract]   [Full Text] [Related]  

  • 46. Controlled comparison of buspirone and clomipramine in obsessive-compulsive disorder.
    Pato MT; Pigott TA; Hill JL; Grover GN; Bernstein S; Murphy DL
    Am J Psychiatry; 1991 Jan; 148(1):127-9. PubMed ID: 1984696
    [TBL] [Abstract][Full Text] [Related]  

  • 47. New pharmacologic approaches to obsessive compulsive disorder.
    Insel TR
    J Clin Psychiatry; 1990 Oct; 51 Suppl():47-51; discussion 56-8. PubMed ID: 2120204
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Obsessive disorder with self-mutilation: a subgroup responsive to pharmacotherapy.
    Primeau F; Fontaine R
    Can J Psychiatry; 1987 Nov; 32(8):699-701. PubMed ID: 3500773
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Serotonin dysfunction syndromes: a functional common denominator for classification of depression, anxiety, and obsessive-compulsive disorder.
    Benkert O; Wetzel H; Szegedi A
    Int Clin Psychopharmacol; 1993 Sep; 8 Suppl 1():3-14. PubMed ID: 8254151
    [No Abstract]   [Full Text] [Related]  

  • 50. Fluoxetine-clomipramine interaction.
    Sternbach H
    J Clin Psychiatry; 1995 Apr; 56(4):171-2. PubMed ID: 7713858
    [No Abstract]   [Full Text] [Related]  

  • 51. Effects of chronic fluoxetine treatment on behavioral and neuroendocrine responses to meta-chlorophenylpiperazine in obsessive-compulsive disorder.
    Hollander E; DeCaria C; Gully R; Nitescu A; Suckow RF; Gorman JM; Klein DF; Liebowitz MR
    Psychiatry Res; 1991 Jan; 36(1):1-17. PubMed ID: 2017519
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clomipramine versus fluoxetine in obsessive-compulsive disorder: a retrospective comparison of side effects and efficacy.
    Jenike MA; Baer L; Greist JH
    J Clin Psychopharmacol; 1990 Apr; 10(2):122-4. PubMed ID: 2140372
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Drug treatment of canine acral lick. An animal model of obsessive-compulsive disorder.
    Rapoport JL; Ryland DH; Kriete M
    Arch Gen Psychiatry; 1992 Jul; 49(7):517-21. PubMed ID: 1385694
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Management of treatment-refractory obsessive compulsive disorder patients.
    Dominguez RA; Mestre SM
    J Clin Psychiatry; 1994 Oct; 55 Suppl():86-92. PubMed ID: 7961537
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Obsessive-compulsive disorder.
    March JS; Johnston H; Greist JH
    Am Fam Physician; 1989 May; 39(5):175-82. PubMed ID: 2497627
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Serotonin and treatment in obsessive-compulsive disorder.
    March JS; Gutzman LD; Jefferson JW; Greist JH
    Psychiatr Dev; 1989; 7(1):1-18. PubMed ID: 2508084
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [The usage of different antidepressants in therapy of obsessive-compulsive disorders].
    Granenov GM; Mosolov SN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2003; 103(7):70-4. PubMed ID: 12938660
    [No Abstract]   [Full Text] [Related]  

  • 58. Peripheral markers of serotonin and dopamine function in obsessive-compulsive disorder.
    Marazziti D; Hollander E; Lensi P; Ravagli S; Cassano GB
    Psychiatry Res; 1992 Apr; 42(1):41-51. PubMed ID: 1603880
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antiobsessive effect of fluoxetine.
    Fontaine R; Chouinard G
    Am J Psychiatry; 1985 Aug; 142(8):989. PubMed ID: 3875293
    [No Abstract]   [Full Text] [Related]  

  • 60. 5-Hydroxytryptamine1A receptor responsivity in obsessive-compulsive disorder. Comparison of patients and controls.
    Lesch KP; Hoh A; Disselkamp-Tietze J; Wiesmann M; Osterheider M; Schulte HM
    Arch Gen Psychiatry; 1991 Jun; 48(6):540-7. PubMed ID: 1674853
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.